Detalhe da pesquisa
1.
Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
BMC Infect Dis
; 24(1): 418, 2024 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38641577